Cite
HARVARD Citation
Berkelmans, G. et al. (n.d.). P4388Treatment decisions based on individual estimated lifetime benefit versus individual estimated 10-year absolute risk reduction: a cost-effectiveness analyses with PCSK9 inhibition. European heart journal. p. . [Online].